trialsTrialPositive

CLARITY-Gastric 01

The first ADC against Claudin 18.2 to prove it extends life, announced July 2026, giving stomach cancer its first ADC beyond HER2.

Met both co-primary endpoints including overall survival (AstraZeneca, 27 July 2026); full data pending congress presentation. Positions CLDN18.2 ADCs after zolbetuximab-chemotherapy or in zolbetuximab-naive patients; CLDN18.2 CAR-T (satri-cel) is the other post-progression option in China.

Setting

Second- or later-line CLDN18.2-positive advanced gastric/GEJ cancer: sonesitatug vedotin (AZD0901/CMG901) vs investigator's choice

Phase

Phase 3

Sponsor

AstraZeneca

Registry

NCT06346392

Headline result

Co-primary endpoints including OS met (July 2026); numbers pending.

Reported

2026

Connected

7top

Evidence strength50/100 · Solid

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 3+30
No structured primary endpoint0
Result: positive+15
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

ProvenanceLast edited 2026-09-08 · Jude Gomila · Spikes: colorectal, gastric, oesophageal cancer deep dive… · diff · file

Sources & links

Data

JSON · ·

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Cancers